Jeroen leads Semarion’s strategy, commercial development and partnering as the company scales adoption of the SemaCyte® platform across drug discovery.

As co-founder and CEO, he connects customer needs, investor strategy and product deployment, building on a background in assay development, advanced therapies, and nanobiotechnology.

Tarun leads Semarion’s technology strategy, platform innovation and manufacturing scale-up, turning the SemaCyte® concept into a robust product suite.

As co-founder and CTO, he brings deep expertise in materials engineering, microfabrication and nanomagnetism, linking device design with scalable production and next-generation product development.

Paul chairs Semarion’s Board and advises the executive team on strategy, partnering, financing and business development as the company scales.

He brings extensive biotech business development experience and is Chief Business Officer at Constructive Bio, having previously held senior commercial leadership roles across the life sciences sector.

Del advises Semarion on product strategy, application development and commercial adoption in the life science tools market.

He co-founded Essen BioScience, helped drive the commercial development of the Incucyte® platform, and is Chair of ELRIG alongside wider leadership, advisory and non-executive roles across the sector.

Russell supports Semarion’s technology development and scientific strategy, drawing on world-leading expertise in nanotechnology, magnetism, electronics and optics.

He is Professor of Experimental Physics at the University of Cambridge, a Fellow of the Royal Society and the founder of multiple technology companies.

Daniel leads Semarion’s applications and cell biology strategy, including field application support, internal assay development, product demonstrations, customer projects and cell biology operations.

He ensures the SemaCyte® platform is translated into robust, user-ready applications across drug discovery, drawing on expertise in DNA damage response, cancer biology and target validation.

Ilaria leads Semarion’s manufacturing operations, including wafer production, wafer coating, assembly, packaging, process improvement and product scale-up.

She brings deep micro- and nanofabrication, surface chemistry and product development experience across life sciences, medical devices and deep tech, helping translate SemaCyte® innovation into reliable, scalable products.

Blaise develops advanced SemaCyte® applications in areas such as oncology, fibrosis and complex cell-based assay development, while supporting high-value customer projects and imaging analysis workflows.

Her background combines stem cell biology, engineered microenvironments and assay development, including PhD research at King’s College London on guiding stem cell differentiation.

Sam develops SemaCyte® applications for antibody drug discovery and supports the integration of the platform with automation tools.

He also contributes to customer projects and internal application development, drawing on experience in cell-based screening, CRISPR workflows, cancer biology and assay optimisation.

Amy supports oncology-focused cell biology projects and the validation of new tools and workflows for the SemaCyte® platform.

She brings extensive cell culture experience across mammalian, primary, stem cell, knockout and hybridoma systems, with a strong track record in cell line development, cryopreservation and laboratory operations.

Atacan drives SemaCyte® end-to-end wafer processing, cleanroom operations and process improvement, with a particular focus on quality control and yield optimisation.

His background spans magnetron sputtering, nanofabrication, lithography, etching and thin-film characterisation, bringing strong semiconductor manufacturing expertise to Semarion’s production team.

Viridiana supports SemaCyte® wafer processing, device fabrication and manufacturing process optimisation, with particular strength in polymer and soft-material microfabrication.

She brings a PhD-level background in physics, microfabrication, organ-on-chip systems, microfluidics and device assembly, helping bridge engineering, biology and production.

Monica supports Semarion’s cleanroom and process operations, helping ensure materials, reagents and workflows are ready for reliable wafer processing and back-of-line coating activities.

She brings SOP-driven laboratory and process experience from cleanroom wafer work and industrial analytical environments, supporting the practical execution of day-to-day manufacturing.

Steve supports Semarion on behalf of Parkwalk Advisors, bringing senior commercial leadership experience across life science tools, diagnostics and international market expansion.

He previously held senior leadership roles at Neogen Europe, helping scale the business through organic growth, new product and market development, and acquisition.

Sean supports Semarion’s commercial strategy, product positioning and business development as the company scales adoption of the SemaCyte® platform across pharmaceutical R&D.

He brings extensive international sales and commercial leadership experience across life sciences, including senior roles at Pelago Bioscience, Horizon Discovery, Roche Diagnostics and Molecular Devices.

Fabrice advises Semarion on compound screening, sample management and the operational requirements of high-throughput drug discovery workflows.

He brings more than 20 years’ experience in automated screening and drug discovery operations, including senior roles at Evotec, Cancer Research Technology, MedImmune, UCB and the ICR.

Patrice supports Semarion’s people strategy, organisational design and HR processes as the company grows its team and operating structure.

She brings more than 20 years’ experience scaling technology and biotech organisations, advising CEOs, Boards and leadership teams across the UK, US and Europe.